Association between depression, anxiety, chronic pain, or opioid use and tumor necrosis factor inhibitor persistence in inflammatory arthritis

Clin Rheumatol. 2022 May;41(5):1323-1331. doi: 10.1007/s10067-021-06045-3. Epub 2022 Jan 27.

Abstract

Introduction: Depression, anxiety, and chronic pain are common comorbidities in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) and may substantially impact patient outcomes. We aimed to determine whether these comorbidities were associated with earlier TNF-inhibitor (TNFi) discontinuation.

Methods: This retrospective cohort study using Optum's de-identified Clinformatics® Data Mart Database 2000-2014 identified patients with RA, PsA, and AS initiating a first TNFi. Depression/anxiety, chronic pain, and opioid use were identified using diagnosis codes and prescription fill data. Cox proportional hazards models were used to compare time to medication discontinuation in patients with or without each of these risk factors and to assess the additive effect of having multiple risk factors.

Results: Among 33,744 patients initiating a TNFi (23,888 RA, 6443 PsA, 3413 AS), depression/anxiety, chronic pain, and opioid use were common, with ≥ 1 risk factor in 48.1%, 42.5%, and 55.4% of patients with RA, PsA, and AS respectively. Each risk factor individually was associated with a 5-7-month lower median treatment persistence in each disease (all p < 0.001). Presence of multiple risk factors had an additive effect on time to discontinuation with HR (95% CI) 1.19 (1.14-1.24), 1.41 (1.33-1.49), and 1.47 (1.43-1.73) for 1, 2, or 3 risk factors respectively in RA. Findings were similar in PsA and AS.

Conclusions: Depression, anxiety, chronic pain, and opioid use are common in inflammatory arthritis and associated with earlier TNFi discontinuation. Recognizing and managing these risk factors may improve treatment persistence, patient outcomes, and cost of care. Key Points • Depression, anxiety, chronic pain, and opioid use are common in patients with inflammatory arthritis. • In patients initiating treatment with a TNF-inhibitor, depression, anxiety, chronic pain, or recent opioid use are associated with sooner discontinuation of TNFi therapy. • Patients with multiple of these risk factors are even more likely to discontinue therapy sooner.

Keywords: Depression; Pain; Rheumatoid arthritis; Spondyloarthritis; Treatment.

MeSH terms

  • Analgesics, Opioid / therapeutic use
  • Antirheumatic Agents* / therapeutic use
  • Anxiety / drug therapy
  • Anxiety / epidemiology
  • Arthritis, Psoriatic* / complications
  • Arthritis, Psoriatic* / diagnosis
  • Arthritis, Psoriatic* / drug therapy
  • Arthritis, Rheumatoid* / complications
  • Arthritis, Rheumatoid* / diagnosis
  • Arthritis, Rheumatoid* / drug therapy
  • Chronic Pain* / drug therapy
  • Chronic Pain* / epidemiology
  • Depression / complications
  • Depression / drug therapy
  • Depression / epidemiology
  • Humans
  • Male
  • Prostate-Specific Antigen / therapeutic use
  • Retrospective Studies
  • Spondylitis, Ankylosing* / complications
  • Spondylitis, Ankylosing* / drug therapy
  • Treatment Outcome
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Analgesics, Opioid
  • Antirheumatic Agents
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha
  • Prostate-Specific Antigen